Skip to main content
. Author manuscript; available in PMC: 2011 Dec 12.
Published in final edited form as: HIV Ther. 2010 Nov;4(6):693–711. doi: 10.2217/hiv.10.47

Table 2.

Changes in fat in subjects switching antiretroviral therapy

Investigators/
study (year)		 Switch Visceral
Adipose
tissue		 Subcutaneous adipose
tissue (limb)		 SAT
(trunk)		 Total fat SAT:total
fat		 Ref.
Stanley et al.
(2009)		 Lopinavir/ritonavir to
atazanavir/ritonavir		 -25 cm2
(22%);
p = 0.047		 NR NR NR NR [20]
SWEET (2009) AZT/3TC to
tenofovir/emtricitabine		 NR Within group change
0.26 kg (4%);p = 0.054
Between group change
0.45 kg; p = 0.025		 NC NC NR [30]
LIPOTEST† (2008) Stavudine to tenofovir NR NR NR 3.9 kg (21%);
p < 0.001		 NR [33]
Madruga et al.†
(2007)		 Stavudine to tenofovir NR 1.3 kg (29%); p < 0.0001 NR NR [31]
Milinkovic et al.‡
(2007)		 Stavudine to tenofovir NR 0.4 kg; p = 0.0003 NR NR NR [32]
ACTG A5110†
(2010)		 Thymidine analog to
abacavir
or
NRTI to
lopinavir/ritonavir +
nevirapine		 Abacavir
-18.3 cm2
(-15%);
p = 0.04;
lopinavir/
ritonavir NC		 Abacavir 2.9 cm2 (18%);
Lopinavir/ritonavir
3.2 cm2 (17%)
Both p < 0.01 (thigh);
no difference between
switch arms		 NR NR NR [48]
NONUKE (2008) NRTI to NNRTI + PI NC 109 cm3 (30%);
= 0.001 (thigh)		 NC NR 0.07
(17%);
p = 0.007		 [48]
MONOI-ANRS 136
(2010)		 Darunavir/ritonavir + NRTI
to darunavir/ritonavir
monotherapy		 NR 0.34 kg (7%); p = 0.011 NC NR NR [59]

Percentage or absolute change calculated from available data.

†

Within-arm p-value reported (otherwise, between-arm p-value reported).

‡

Percentage change not calculated secondary to available data.

3TC: Lamivudine;AZT: Zidovudine; NC: No (significant) change; NNRTI: Non-nucleoside reverse transcriptase inhibitor; NR: Not reported or not performed; NRTI: Nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor; SAT: Subcutaneous adipose tissue.